Page last updated: 2024-10-25

cimetidine and Myeloproliferative Disorders

cimetidine has been researched along with Myeloproliferative Disorders in 2 studies

Cimetidine: A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.
cimetidine : A member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach.

Myeloproliferative Disorders: Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19902 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hess, CE1
Berild, D1
Hasselbalch, H1

Other Studies

2 other studies available for cimetidine and Myeloproliferative Disorders

ArticleYear
Cimetidine for the treatment of pruritus.
    The New England journal of medicine, 1979, Feb-15, Volume: 300, Issue:7

    Topics: Cimetidine; Guanidines; Humans; Myeloproliferative Disorders; Pruritus

1979
[Itching of the skin in myeloproliferative disease treated with cimetidine].
    Ugeskrift for laeger, 1985, Apr-22, Volume: 147, Issue:17

    Topics: Aged; Cimetidine; Female; Humans; Male; Middle Aged; Myeloproliferative Disorders; Pruritus

1985